Omar Dina, Alsanae Hala, Al Khawari Mona, Abdulrasoul Majedah, Rahme Zahraa, Al Refaei Faisal, Behbehani Kazem, Shaltout Azza
Dasman Diabetes Institute, Al-Amiri Hospital, Faculty of Medicine, University of Kuwait, Kuwait, Kuwait.
Open Cardiovasc Med J. 2017 Feb 28;11:19-27. doi: 10.2174/1874192401711010019. eCollection 2017.
To audit the current clinical practice of continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetes mellitus (T1D) in children and adolescents attending a single centre in Kuwait.
A one year retrospective audit was performed in children and adolescents with T1D on CSII, who attended the paediatric diabetes clinic, Dasman Diabetes Institute during 2012. The primary outcome measure was glycaemic control as evidenced by glycated haemoglobin (HbA1c) level and the secondary outcome measures were the frequency of monitoring of the risk for microvascular complications and occurrence of acute complications and adverse events.
58 children and adolescents (mean age ± SD: 12.6 ± 4.1 years) were included. Mean HbA1c at baseline was 8.8% (72.7 mmol/mol) and 8.9% (73.8 mmol/mol) at the end of a 12 months observation period. Children with poor control (HbA1c >9.5% (80 mmol/mol) had a significant 1.4% reduction in HbA1c compared with the overall reduction of 0.1% (p=0.7). Rate of screening for cardiovascular risk factors and for long term complications were well documented. However, there was underreporting of acute complications such as severe hypoglycaemia and diabetic ketoacidosis. Only 1.7% of patients discontinued the pump.
There was no significant change in HbA1c values at the end of 12 months follow up. However, HbA1c values in poorly controlled children improved. CSII requires care by skilled health professionals as well as education and selection of motivated parents and children.
对科威特一个中心收治的儿童及青少年1型糖尿病(T1D)患者持续皮下胰岛素输注(CSII)的当前临床实践进行审核。
对2012年在达斯曼糖尿病研究所儿科糖尿病门诊接受CSII治疗的T1D儿童及青少年进行为期一年的回顾性审核。主要结局指标为糖化血红蛋白(HbA1c)水平所反映的血糖控制情况,次要结局指标为微血管并发症风险监测频率、急性并发症及不良事件的发生情况。
纳入58名儿童及青少年(平均年龄±标准差:12.6±4.1岁)。基线时平均HbA1c为8.8%(72.7 mmol/mol),12个月观察期结束时为8.9%(73.8 mmol/mol)。控制不佳(HbA1c>9.5%(80 mmol/mol))的儿童HbA1c显著降低1.4%,而总体降低0.1%(p=0.7)。心血管危险因素及长期并发症的筛查率记录良好。然而,严重低血糖和糖尿病酮症酸中毒等急性并发症报告不足。仅1.7%的患者停止使用胰岛素泵。
12个月随访结束时HbA1c值无显著变化。然而,控制不佳的儿童HbA1c值有所改善。CSII需要专业医护人员的护理以及对积极主动的家长和儿童进行教育与筛选。